p210 BCR-ABL1 in B-ALL (~30% of adult Ph+ ALL, much rarer in pediatric) — needs careful d...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BCR-ABL1-P210-BALL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-B-ALL |
| Sources | SRC-BLAST-GOKBUGET-2018 SRC-CIVIC SRC-NCCN-BCELL-2025 |
Actionability Facts
| Biomarker | BIO-BCR-ABL1 |
|---|---|
| Variant | p210 (e13a2 / e14a2) — atypical Ph+ B-ALL |
| Disease | DIS-B-ALL |
| ESCAT tier | IIA |
| Recommended combinations | ponatinib + hyper-CVAD, dasatinib + blinatumomab, imatinib + chemotherapy |
| Contraindicated monotherapy | TKI alone without chemo/immunotherapy backbone |
| Evidence summary | p210 BCR-ABL1 in B-ALL (~30% of adult Ph+ ALL, much rarer in pediatric) — needs careful distinction from CML in lymphoid blast crisis. Treatment principles mirror p190 Ph+ ALL: TKI + chemotherapy or TKI + blinatumomab. Outcomes data limited by rarity but appear comparable to p190. |
Notes
ESCAT IIA — strong retrospective evidence; treatment paradigm borrowed from p190 trials. Ensure CML in lymphoid BC is excluded (history, bone marrow, BCR-ABL transcript ratio).
Used By
No reverse references found in the YAML corpus.